Immune to Cancer: The CRI Blog
- 
   
   
        Voices Amongst the Crowd at 2018 TCS New York City MarathonSixteen Team CRI runners ran the 26.2 mile 2018 TCS New York City Marathon and raised an… 
- 
   
   
        Fundraising and Fighting Cancer with Music for a CauseOn September 28, 2018, Conversing with Oceans organized a concert and fundraiser in the Bronx to support… 
- 
   
   
        CRI Celebrates its 65th BirthdayOn Thursday, October 25, the Cancer Research Institute held its annual awards gala to celebrate its 65th… 
- 
   
   
        CICON18 Day 3 Update: Targeting Tumor Mutations with Vaccine-Based ImmunotherapiesThe third day of CICON18 explored cutting-edge strategies to identify and target the mutated markers that distinguish… 
- 
   
   
        Dr. James P. Allison, CRI Scientific Director, Awarded 2018 Nobel Prize along with Dr. Tasuku HonjoDr. Allison’s discoveries and determination led to the development of the first FDA-approved checkpoint immunotherapy 
- 
   
   
        Cemiplimab Becomes First Treatment Approved for Advanced Cutaneous Squamous Cell CarcinomaImmunotherapy is now approved for patients with advanced forms of the second most common form of skin… 
- 
   
   
        CICON18 Preview: Translating Science into SurvivalHighlights from the upcoming International Cancer Immunotherapy Conference (CICON18), including regulating T cell response, tackling the tumor… 
- 
   
   
        Recapping the Third Annual Rational Combinations 360°In September, experts across the immunology and immunotherapy spectrum convened in Philadelphia to discuss the latest advances… 

Join CRI in Shaping the Future of Immunotherapy
Support the pioneering work of CRI in advancing immunotherapy.
